Publications by authors named "Jaume Capdevila"

Claim this Profile
C
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).
Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo, Marta Benavent Viñuales, Rocio Garcia-Carbonero

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Camilo Jimenez, Mikkel Andreassen, Alice Durand, Sophie Moog, Andrew Hendifar, Jaume Capdevila

N Engl J Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in -Mutant Medullary Thyroid Cancer.
Rossella Elisei, Lori J Wirth, Jaume Capdevila, Ana Oliveira Hoff, Makoto Tahara

Thyroid· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking Adversely Affects Survival of Metastatic Lung Carcinoid Patients: Analysis of a Large International Audit and Prognostic Models for Metastasis-Free Survival and Overall Survival.
Amy Clarke, Aimee Cunningham, Alejandro Garcia-Alvarez, Laura Spurgeon, Robert Morgan, Jaume Capdevila

Neuroendocrinology· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus.
Aleš Ryška, Jaume Capdevila, Matthias S Dettmer, Rossella Elisei, Dagmar Führer

Eur Thyroid J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib as salvage therapy in advanced and progressive GI-NET.
Annie Mathew, Jaume Capdevila, Nicole Unger, Wolfgang Fendler, Sarah Theurer

Endocr Relat Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Merkel cell carcinoma: long-term outcomes after radiotherapy treatment.
Enar Recalde Vizcay, Begoña Navalpotro Yagüe, Carla Ferrandiz-Pulido, Jorge Hernando Cubero, Jaume Capdevila

Clin Transl Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1).
Andrea Cercek, Jean-Baptiste Bachet, Jaume Capdevila, Naureen Starling, Eric Chen

Clin Colorectal Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA Methylation Dynamics and Prognostic Implications in Metastatic Differentiated Thyroid Cancer.
Helena Rodríguez-Lloveras, Carles Zafon, Carmela Iglesias, Jennifer Marcos-Ruiz, Joan Gil, Jaume Capdevila

Thyroid· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes.
Carlota Arenillas, Lucía Celada, José Ruiz-Cantador, Bruna Calsina, Debayan Datta, Jaume Capdevila

Cancer Discov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spanish consensus on the diagnosis and management of adrenocortical carcinoma.
Marta Araujo-Castro, Cristina Álvarez-Escola, Ana Casteràs, Alberto Carmona-Bayonas, María-Dolores Chiara, Jaume Capdevila

Endocr Relat Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer.
Maria Balaguer-Montero, Adrià Marcos Morales, Marta Ligero, Christina Zatse, David Leiva, Jaume Capdevila

Cell Rep Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized clinical trial evaluating the impact on survival and quality of life of Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina-Cerrillo

BMC Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study.
Maribel Del Olmo-García, Lorena Hernandez-Rienda, Rocio Garcia-Carbonero, Jorge Hernando, Ana Custodio, Jaume Capdevila

Oncologist· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review.
Natalia Soledad Tissera, Francesca Balconi, Alejandro García-Álvarez, Jorge Hernando Cubero, Juan Manuel O'Connor, Jaume Capdevila

Cancer Treat Rev· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials.
Sara Gil-Bernabé, Lucía García-DeLaFuente, Alejandro García-Álvarez, Ginesa García-Rostán, Jaume Capdevila

Am J Med Genet C Semin Med Genet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
Laurent Mortier, Lisa Villabona, Ben Lawrence, Ana Arance, Marcus O Butler, Jaume Capdevila

Am J Clin Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force.
Anna Koumarianou, Pier Luigi Filosso, Lisa Bodei, Justo P Castano, Lynnette Fernandez-Cuesta, Jaume Capdevila

J Neuroendocrinol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Marcia S Brose, Jaume Capdevila, Rossella Elisei, Lars Bastholt, Dagmar Führer-Sakel

Endocr Relat Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).
Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, Paula Jimenez-Fonseca, Alex Teule

Nat Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, Patrick Schöffski, Yann Godbert, Jaume Capdevila

Front Endocrinol (Lausanne)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Simron Singh, Daniel Halperin, Sten Myrehaug, Ken Herrmann, Marianne Pavel, Jaume Capdevila

Lancet· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours" [Eur J Cancer 188 (2023) 39-48].
Jorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, Eric Raymond, Philippe Ruszniewski, Jaume Capdevila

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum for: Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer.
Olivia Prior, Carlos Macarro, Víctor Navarro, Camilo Monreal, Marta Ligero, Jaume Capdevila

Radiol Artif Intell· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Simron Singh, Diego Ferone, Jaume Capdevila, Jennifer Ang Chan, Wouter W de Herder

Trials· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis